Daesung Group, an power and surroundings conglomerate, held the 2025 Daesung Haegang Science Discussion board in Seoul on Tuesday, highlighting the most recent biotechnology improvements within the period of synthetic intelligence (AI).
Marking its eighth version this yr, the annual discussion board explored the theme “Bio-Innovation within the AI Period,” bringing collectively consultants and business leaders to share their insights on the convergence of AI and biotechnology and their future improvement trajectory.
On the discussion board, Lee Sang-yup, vice chairman for analysis on the Korea Superior Institute of Science and Know-how, delivered a keynote speech below the title “AI for Organic Engineering.” He introduced sensible methods and case research on how AI is being utilized in organic engineering analysis and improvement.
College of Toronto professor Philip Kim adopted with a presentation on protein engineering with AI, whereas Kakao Healthcare CEO Hwang Hee mentioned how AI and large information are driving innovation in digital well being care.
Daesung Group Chairman Kim Younger-hoon delivers his opening speech for the 2025 Daesung Haegang Science Discussion board in Seoul, Tuesday. Courtesy of Daesung Group
“The convergence of AI and biotechnology is anticipated to convey modern and disruptive applied sciences to the sphere of life sciences,” Daesung Group Chairman Kim Younger-hoon mentioned.
“Via such advances, I hope we will transfer nearer to realizing humanity’s dream of life extension whereas strengthening Korea’s nationwide competitiveness by its proprietary biotechnology.”
Daesung Group has been making aggressive strategic investments into AI and biotechnology by its subsidiary, Daesung Personal Fairness.
Amongst its portfolio corporations, 1STBIO is enhancing the accuracy of novel drug improvement by using AI, and has just lately established cooperation with Nvidia for an AI-driven drug discovery mannequin. One other portfolio agency, Qureator, has launched a know-how that mixes organ-on-a-chip and AI to exactly replicate human illness environments, considerably decreasing failure charges in scientific trials.
